Jack Wahlen

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

Nicole Sherry, William Hagopian, Johnny Ludvigsson et al. · The Lancet · 2011 · 489 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)

A. J. Garber, Jack Wahlen, Tyler S. Wahl et al. · Diabetes Obesity and Metabolism · 2005 · 261 citations · Full text

Medicine, Endocrinology, Pharmacology +17

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

María J. Redondo, Susan Geyer, Andrea K. Steck et al. · Diabetes Care · 2018 · 169 citations · Full text

Life Sciences, Endocrinology, Genetics +17

Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial

Roy W. Beck, Tonya D. Riddlesworth, Katrina J. Ruedy et al. · The Lancet Diabetes & Endocrinology · 2017 · 119 citations

Medicine, Internal Medicine, Diabetology +14

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 95 citations · Full text

Medicine, Endocrinology, Pharmacology +14